These promising results eventually led to the development of another anti-IgE monoclonal antibody, omalizumab, which initially gained FDA approval in 2003 for the treatment of asthma, and later for chronic spontaneous urticaria, and chronic rhinosinusitis. This evidence concerns the gene IGHE and asthma.